Clinical Advances in Nasopharyngeal Carcinoma

Experts on nasopharyngeal carcinoma (NPC) provide an overview of the disease, highlighting its incidence, how it’s differentiated from other head and neck cancers, and the benefits of multidisciplinary care.

Shravan Kandula, MD, reviews the current guidelines for the treatment of patients with nasopharyngeal carcinoma.

Victoria M. Villaflor, MD, provides insights on the role of immune checkpoint inhibitors in treating nasopharyngeal carcinoma, focusing on the JUPITER and POLARIS-2 clinical trials.

A medical oncologist discusses the value of PD-L1 as a biomarker in the treatment of patients with nasopharyngeal carcinoma.

Shravan Kandula, MD, reviews findings from the DIPPER trial, which is investigating adjuvant PD-1 blockade with camrelizumab in patients with nasopharyngeal carcinoma.

Experts on nasopharyngeal carcinoma outline the role of immunotherapy and discuss external factors that inform treatment decisions.

Victoria M. Villaflor, MD, highlights ways to mitigate adverse events for patients receiving treatment for nasopharyngeal carcinoma.

The panel provides clinical insights on nasopharyngeal carcinoma treatment practices and outlines unmet needs in the current therapeutic landscape.

Victoria M. Villaflor, MD, discusses the integration of PD-1 inhibitors into standard treatment practices for patients with nasopharyngeal carcinoma.

Shravan Kandula, MD, presents the case of a patient with locally recurrent nasopharyngeal carcinoma.

The panel provides clinical insights on the treatment of a patient with metastatic EBV-positive nasopharyngeal carcinoma.